159 related articles for article (PubMed ID: 16683063)
21. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
22. Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy.
Baulac M; Byrnes W; Williams P; Borghs S; Webster E; De Backer M; Dedeken P
Acta Neurol Scand; 2017 Apr; 135(4):434-441. PubMed ID: 27714769
[TBL] [Abstract][Full Text] [Related]
23. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
24. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Rosenow F; Schade-Brittinger C; Burchardi N; Bauer S; Klein KM; Weber Y; Lerche H; Evers S; Kovac S; Hallmeyer-Elgner S; Winkler G; Springub J; Niedhammer M; Roth E; Eisensehr I; Berrouschot J; Arnold S; Schröder M; Beige A; Oertel WH; Strzelczyk A; Haag A; Reif PS; Hamer HM;
J Neurol Neurosurg Psychiatry; 2012 Nov; 83(11):1093-8. PubMed ID: 22595362
[TBL] [Abstract][Full Text] [Related]
25. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.
Chung S; Ceja H; Gawłowicz J; Avakyan G; McShea C; Schiemann J; Lu S
Epilepsy Res; 2012 Aug; 101(1-2):92-102. PubMed ID: 22516508
[TBL] [Abstract][Full Text] [Related]
26. Levetiracetam monotherapy--outcomes from an epilepsy clinic.
Stephen LJ; Kelly K; Parker P; Brodie MJ
Seizure; 2011 Sep; 20(7):554-7. PubMed ID: 21531583
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients.
Heo K; Lee BI; Yi SD; Huh K; Kim JM; Lee SA; Shin DJ; Song HK; Lee SK; Kim JY; Lu S; Dubois C; Tonner F
Seizure; 2007 Jul; 16(5):402-9. PubMed ID: 17369059
[TBL] [Abstract][Full Text] [Related]
29. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
von Stuelpnagel C; Holthausen H; Kluger G
Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
[TBL] [Abstract][Full Text] [Related]
30. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Zesiewicz TA; Sullivan KL; Maldonado JL; Tatum WO; Hauser RA
Mov Disord; 2005 Sep; 20(9):1205-9. PubMed ID: 15954135
[TBL] [Abstract][Full Text] [Related]
31. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.
Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A
Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681
[TBL] [Abstract][Full Text] [Related]
32. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland.
Steinhoff BJ; Trinka E; Wieser HG;
Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
Grant R; Shorvon SD
Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
[TBL] [Abstract][Full Text] [Related]
34. [Follow-up study on levetiracetam monotherapy in children with epilepsy].
Gao ZJ; Jiang YW
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Dec; 10(6):711-4. PubMed ID: 19102836
[TBL] [Abstract][Full Text] [Related]
35. An open-label study of levetiracetam for the treatment of social anxiety disorder.
Simon NM; Worthington JJ; Doyle AC; Hoge EA; Kinrys G; Fischmann D; Link N; Pollack MH
J Clin Psychiatry; 2004 Sep; 65(9):1219-22. PubMed ID: 15367048
[TBL] [Abstract][Full Text] [Related]
36. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany.
Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E
Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573
[TBL] [Abstract][Full Text] [Related]
37. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
38. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
39. A pilot trial of levetiracetam in eyelid myoclonia with absences (Jeavons syndrome).
Striano P; Sofia V; Capovilla G; Rubboli G; Di Bonaventura C; Coppola A; Vitale G; Fontanillas L; Giallonardo AT; Biondi R; Romeo A; Viri M; Zara F; Striano S
Epilepsia; 2008 Mar; 49(3):425-30. PubMed ID: 18248445
[TBL] [Abstract][Full Text] [Related]
40. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial.
Kim JH; Lee SK; Loesch C; Namgoong K; Lee HW; Hong SB;
Epilepsia; 2017 Apr; 58(4):e70-e74. PubMed ID: 28395124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
